Clinical trial of gabexate in the prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis
Braz. j. med. biol. res
;
39(1): 85-90, Jan. 2006. tab
Artigo
em Inglês
| LILACS
| ID: lil-419156
ABSTRACT
The objective of the present study was to determine the efficacy of prophylactic administration of gabexate for the prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis, hyperamylasemia and pancreatic pain. Patients scheduled for ERCP were randomized into two groups in a double-blind manner the patients in the gabexate group were treated with continuous intravenous infusion of 300 mg gabexate dissolved in 500 mL Ringer's solution at 111 mL/h, starting 30 min before the endoscopic maneuvers and continuing up to 4 h after them; placebo group patients were treated only with Ringer's solution also starting 30 min before the endoscopic maneuvers and continuing up to 4 h. Data for 193 patients were analyzed. The incidence of post-ERCP pancreatitis was 3 patients (3.1 percent) in the gabexate group and 10 (10.5 percent) in the placebo group (P = 0.040). The incidence of hyperamylasemia was 33 patients (33.7 percent) in the gabexate group and 42 (43.7 percent) in the placebo group (P = 0.133). The incidence of pancreatic pain was 15 patients (15.3 percent) in the gabexate group and 28 (29.5 percent) in the placebo group (P = 0.018). The results suggest that a 4.5-h infusion of gabexate (for a total of 300 mg) could prevent post-ERCP pancreatitis and pancreatic pain.
Texto completo:
DisponíveL
Índice:
LILACS (Américas)
Assunto principal:
Pancreatite
/
Dor Abdominal
/
Inibidores de Serina Proteinase
/
Colangiopancreatografia Retrógrada Endoscópica
/
Gabexato
/
Hiperamilassemia
Tipo de estudo:
Ensaio Clínico Controlado
/
Estudo de etiologia
/
Estudo observacional
/
Fatores de risco
Limite:
Feminino
/
Humanos
/
Masculino
Idioma:
Inglês
Revista:
Braz. j. med. biol. res
Assunto da revista:
Biologia
/
Medicina
Ano de publicação:
2006
Tipo de documento:
Artigo
País de afiliação:
China
Instituição/País de afiliação:
Shanghai Second Medical University/CN
Similares
MEDLINE
...
LILACS
LIS